The Mayo Clinic Cancer Center (MCCC) is a comprehensive cancer center that has been a designated NCI Center in Rochester, MN (MCR) since 1974. Today, MCCC includes not only MCR, but also sites in Jacksonville, Florida (MCF), and Scottsdale/Phoenix, Arizona (MCA). Each site has a thriving clinical cancer practice with clinical investigators at each of the sites, and a critical mass of basic science and population sciences faculty as well. In 2013, NCI recognized MCCC as an integrated comprehensive cancer based at all 3 sites, based on shared leadership, shared research including multi-investigator grant activity, co-author publications, and enterprise-wide clinical protocol activity. Robert B. Diasio, MD, has been director of MCCC since 2006, leading the center through successful competitive renewals of the CCSG application in 2008 and later in 2013. Since 2013, the center has continued to flourish with strong cancer-focused research, many examples of team science (e.g., SPOREs), an increase in high impact publications and many examples of translational research, and, most importantly, many examples of practice-changing approaches to cancer care. Following strategic planning in 2014, MCCC now has the following aims: 1. To advance the cancer-focused research of each of our MCCC members within our existing 10 Programs and within potential future Programs in order to promote high impact science. 2. To advance interactions of our MCCC members within Programs (intraprogrammatic); across Programs (interprogrammatic); and with individuals at other Cancer Centers and institutions (interinstitutional). 3. To advance new approaches for the treatment of cancer by facilitating translation of basic science concepts from the laboratory to the clinic within MCCC. 4. To continue to build and to further integrate cancer research activities at MCA, MCF, and MCR and to extend these activities to the Mayo Clinic Health System (MCHS). 5. To further develop cancer education for patients, high school, college, and graduate students, postgraduates, as well as faculty. 6. To extend our cancer research, practice, and education within our catchment areas at each of our 3 major sites in MCA, MCF, and MCR and the MCHS with the ultimate goal of lessening cancer burden. We will use these 6 specific aims to further the mission of MCCC: (1) to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and (2) through education and direct application of the results of such research, to translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy.

Public Health Relevance

This Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted at the Mayo Clinic Cancer Center. The Center's ultimate goal is to lessen the cancer burden on patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320

Showing the most recent 10 out of 1129 publications